 |
|
Oral Topiramate Reduces the Consequences of Drinking and Improves the Quality of Life of Alcohol-Dependent Individuals
A Randomized Controlled Trial
Bankole A. Johnson, MD, PhD;
Nassima Ait-Daoud, MD;
Fatema Z. Akhtar, MS;
Jennie Z. Ma, PhD (Biostatistics)
Arch Gen Psychiatry. 2004;61:905-912.
Background Topiramate, a fructopyranose derivative, was superior to placebo at improving the drinking outcomes of alcohol-dependent individuals.
Objectives To determine whether topiramate, compared with placebo, improves psychosocial functioning in alcohol-dependent individuals and to discover how this improvement is related to heavy drinking behavior.
Design Double-blind, randomized, controlled, 12-week clinical trial comparing topiramate vs placebo for treating alcohol dependence (1998-2001).
Participants One hundred fifty alcohol-dependent individuals, diagnosed using the DSM-IV.
Interventions Seventy-five participants received topiramate (escalating dose of 25 mg/d to 300 mg/d), and 75 had placebo and weekly standardized medication compliance management.
Main Outcome Measures Three elements of psychosocial functioning were measured: clinical ratings of overall well-being and alcohol-dependence severity, quality of life, and harmful drinking consequences. Overall well-being and dependence severity and quality of life were analyzed as binary responses with a generalized estimating equation approach; harmful drinking consequences were analyzed as a continuous response using a mixed-effects, repeated-measures model.
Results Averaged over the course of double-blind treatment, topiramate, compared with placebo, improved the odds of overall well-being (odds ratio [OR] = 2.17; 95% confidence interval [CI], 1.16-2.60; P = .01); reported abstinence and not seeking alcohol (OR = 2.63; 95% CI, 1.52-4.53; P = .001); overall life satisfaction (OR = 2.28; 95% CI, 1.21-4.29; P = .01); and reduced harmful drinking consequences (OR = –0.07; 95% CI, –0.12 to –0.02, P = .01). There was a significant shift from higher to lower drinking quartiles on percentage of heavy drinking days, which was associated with improvements on all measures of psychosocial functioning.
Conclusions As an adjunct to medication compliance enhancement treatment, topiramate (up to 300 mg/d) was superior to placebo at not only improving drinking outcomes but increasing overall well-being and quality of life and lessening dependence severity and its harmful consequences.
From the Department of Psychiatry, The University of Texas Health Science Center at San Antonio (Drs Johnson, Ait-Daoud, and Ma and Ms Akhtar).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals With Topiramate Treatment: US Multisite Randomized Controlled Trial
Johnson et al.
Arch Intern Med 2008;168:1188-1199.
ABSTRACT
| FULL TEXT
Topiramate-Induced Palinopsia
Fontenelle
J. Neuropsychiatry Clin. Neurosi. 2008;20:249-250.
FULL TEXT
Longitudinal Course of Substance Treatment Benefits in Older Male Veteran At-Risk Drinkers
Zanjani et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2008;63:98-106.
ABSTRACT
| FULL TEXT
Topiramate for Treating Alcohol Dependence: A Randomized Controlled Trial
Johnson et al.
JAMA 2007;298:1641-1651.
ABSTRACT
| FULL TEXT
Drs. Barzman and DelBello Reply
BARZMAN and DelBello
Am. J. Psychiatry 2007;164:527-528.
FULL TEXT
COMPLETE AND PROLONGED SUPPRESSION OF SYMPTOMS AND CONSEQUENCES OF ALCOHOL-DEPENDENCE USING HIGH-DOSE BACLOFEN: A SELF-CASE REPORT OF A PHYSICIAN
AMEISEN
Alcohol Alcohol 2005;40:147-150.
ABSTRACT
| FULL TEXT
Anticonvulsant May Have Role In Treating Alcohol Abuse
Rosack
Psychiatr. News 2004;39:28-28.
FULL TEXT
|
